The University of Chicago Header Logo

Connection

Christopher Winslow to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Christopher Winslow has written about Antineoplastic Agents.
Christopher Winslow
Connection Strength
0.099
Antineoplastic Agents
  1. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.099
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.